Ferralet 90

Manufacturer
Mission Pharmacal Company
Effective date
2026-01-07
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
8
Source
full-release
Hydrated at
2026-05-31 21:54:20

Label at a glance#

ProductFerralet 90
Active ingredientIRON, FOLIC ACID, CYANOCOBALAMIN, ASCORBIC ACID, DOCUSATE SODIUM
Label structure16 sections

Boxed warning

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

Indications and uses

Ferralet ® 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, postsurgical convalescence, and dietary needs.

Dosage and administration

One tablet daily or as directed by a physician.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Each green film-coated tablet for oral administration contains:

Iron (Carbonyl iron, ferrous gluconate)90  mg
Folic Acid 11  mg
Vitamin B 12(Cyanocobalamin) 12  mcg
Vitamin C (Ascorbic acid)120  mg
Docusate sodium 5050  mg

Inactive Ingredients:Povidone, croscarmellose sodium, acrylic resin, color added, magnesium stearate, FD&C Yellow No. 5, magnesium silicate, FD&C Blue No. 1, polyethylene glycol, vitamin A palmitate, ethyl vanillin.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Oral iron is absorbed most efficiently when administered between meals. Iron is critical for normal hemoglobin synthesis to maintain oxygen transport energy production and proper function of cells. Adequate amounts of iron are necessary for effective erythropoiesis. Iron also serves as a cofactor of several essential enzymes, including cytochromes, which are involved in electron transport. Folic acid is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is the precursor of tetrahydrofolic acid, which is involved as a cofactor for transformylation reactions in the biosynthesis of purines and thymidylates of nucleic acids. Deficiency of folic acid may account for the defective deoxyribonucleic acid (DNA) synthesis that leads to megaloblast formation and megaloblastic macrocytic anemias. Vitamin B 12is essential to growth, cell reproduction, hematopoiesis, nucleic acid, and myelin synthesis. Deficiency may result in megaloblastic anemia or pernicious anemia.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Ferralet ®90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, postsurgical convalescence, and dietary needs.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Hypersensitivity to any of the ingredients. Hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

WARNING

WARNINGS SECTION

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B 12is deficient.

WARNING

BOXED WARNING SECTION

Accidental overdose of iron-containingproducts is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Take 2 hours after meals. Do not exceed recommended dose. Discontinue use if symptoms of intolerance appear. The type of anemia and underlying cause or causes should be determined before starting therapy with Ferralet ®90 tablets. Ensure Hgb, Hct, reticulocyte count are determined before starting therapy and periodically thereafter during prolonged treatment. Periodically review therapy to determine if it needs to be continued without change or if a dose change is indicated. This product contains FD&C Yellow No. 5 (tartrazine, which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Folic Acid

SPL UNCLASSIFIED SECTION

Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Pernicious anemia should be excluded before using these products since folic acid may mask the symptoms of pernicious anemia.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

GERIATRIC USE SECTION

Dosing for elderly patients should be cautious. Due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy, dosing should start at the lower end of the dosing range.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Adverse reactions with iron therapy may include GI irritation, constipation, diarrhea, nausea, vomiting, and dark stools. Adverse reactions with iron therapy are usually transient. Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

DRUG INTERACTIONS

SPL UNCLASSIFIED SECTION

Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.

OVERDOSAGE

OVERDOSAGE SECTION

Symptoms: abdominal pain, metabolic acidosis, anuria, CNS damage, coma, convulsions, death, dehydration, diffuse vascular congestion, hepatic cirrohosis, hypotension, hypothermia, lethargy, nausea, vomiting, diarrhea, tarry stools, melena, hematemesis, tachycardia, hyperglycemia, drowsiness, pallor, cyanosis, lassitude, seizures, and shock.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

One tablet daily or as directed by a physician.

NOTICE

SPL UNCLASSIFIED SECTION

Contact with moisture can discolor or erode the tablet.

Do not chew tablet.

HOW SUPPLIED

HOW SUPPLIED SECTION

Ferralet ®90 (NDC 0178-0089-90) is a green, modified rectangle shaped, film-coated tablet, debossed with "F6" on one side and blank on the other, and packaged in bottles of 90. Store at 25°C (77°F). Excursions permitted to 15°-30°C (59°-86°F). (See USP Controlled Room Temperature.)

SPL UNCLASSIFIED SECTION

To reporta serious adverse event or obtain product information, call (210) 696-8400.

If you have questions about Ferralet ®90 please call: 1 (800) 531-3333

MISSION PHARMACAL COMPANY

San Antonio, TX USA 78230 1355

www.missionpharmacal.com

Copyright © 2020 Mission Pharmacal Company. All rights reserved

L00890R0520

SPL PATIENT PACKAGE INSERT SECTION

Ferralet®90
90 mg Dual-Iron Delivery

RX ONLY

THERAPEUTIC
GUIDELINES FOR
THE PATIENT

Some facts you should know about Iron Deficiency Anemia

Iron Deficiency Anemia, or IDA, is a common type of anemia. It's a condition in which blood lacks an adequate supply of healthy red blood cells. These cells carry oxygen to tissues. It is oxygenated blood that gives your body energy and your skin a healthy color.

As the name suggests, Iron Deficiency Anemia results from insufficient iron. Your body needs iron to make a substance called hemoglobin. It's the hemoglobin in red blood cells that enables them to carry oxygen.

What causes IDA?

There are many causes of IDA. These include:

  • A diet consistently low in iron
  • Blood loss due to heavy menstrual bleeding
  • Poor iron absorption from food due to intestinal surgery or diseases of the intestine
  • Pregnancy (when the need for iron increases significantly)

Women in general are at higher risk of IDA, not only because they lose blood during menstruation but also because their bodies store less iron.

How common is it?

IDA is a common nutritional deficiency, with women most widely affected. Up to 20% of women have IDA.

What are the symptoms?

Some of the symptoms most commonly associated with IDA are fatigue, weakness, and headache. Symptoms may also include light-headedness, pale skin, shortness of breath, and cold hands and feet, among others. As the body becomes more deficient in iron and anemia worsens, the symptoms worsen as well.

How is IDA diagnosed?

A diagnosis is made primarily through blood tests. The doctor checks your hematocrit, the percentage of your blood volume made up of red blood cells and hemoglobin. A lower than normal hemoglobin level indicates anemia. Also, blood tests for IDA typically include a measurement of ferritin, a protein that helps store iron in your body. When the level of ferritin is low, usually the level of iron is, too. If a patient tests positive for IDA, additional tests may be ordered to identify an underlying cause.

Does IDA lead to health complications?

Mild cases of IDA usually don't cause complications. However, left untreated, IDA can increase in severity and contribute to serious health problems. For example, it may lead to a rapid or irregular heartbeat, a complicated pregnancy that can put the mother at risk for a premature delivery or low-birth-weight baby, and delayed growth in infants and children. The good news is that, because IDA is easily treatable, its potential health consequences are generally avoidable.

How is IDA treated?

It's essential to increase the amount of iron in your diet. Foods rich in iron include meat, fish, poultry, and whole grain breads. However, in most cases of IDA, diet alone isn't enough to correct the problem. Iron supplementation is usually needed for several months. Your doctor has prescribed Ferralet ®90, a safe and effective iron supplement to help restore your body's iron to normal levels. Plus, it offers the convenience of once-daily dosing. Together with an iron-rich diet, taking Ferralet ®90 every day can make a big difference in helping restore your body's iron, and with it your energy and overall feeling of well-being.

PRINCIPAL DISPLAY PANEL - 90 mg Tablet Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC0178-0089-90

Rx Only

Ferralet®90

90 mg Dual-Iron Delivery

90 Coated Tablets

MISSION ®PHARMACAL

LabelLabel

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
836270ascorbic acid 120 MG / docusate sodium 50 MG / folic acid 1 MG / iron carbonyl 90 MG / vitamin B12 0.012 MG Oral Tablet [Ferralet 90]SBD8
836268ascorbic acid 120 MG / docusate sodium 50 MG / folic acid 1 MG / iron carbonyl 90 MG / vitamin B12 0.012 MG Oral TabletSCD8
836268cyanocobalamin 12 MCG / docusate sodium 50 MG / folic acid 1 MG / iron carbonyl 90 MG / vitamin C 120 MG Oral TabletSY8
836270Ferralet 90 Oral TabletSY8
836268vit-C 120 MG / DOSS sodium 50 MG / folate 1 MG / iron carbonyl 90 MG / vitamin B12 0.012 MG Oral TabletSY8
836270vit-C 120 MG / DOSS sodium 50 MG / folate 1 MG / iron carbonyl 90 MG / vitamin B12 0.012 MG Oral Tablet [Ferralet 90]SY8
836268vitamin C 120 MG / DOSS sodium 50 MG / folate 1 MG / iron carbonyl 90 MG / vitamin B12 0.012 MG Oral TabletSY8
836270vitamin C 120 MG / DOSS sodium 50 MG / folate 1 MG / iron carbonyl 90 MG / vitamin B12 0.012 MG Oral Tablet [Ferralet 90]SY8

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ASCORBIC ACID Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
CYANOCOBALAMIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130301780089903GTIN-13: 0301780089903
EAN-13: 0301780089903
GTIN-12: 301780089903
UPC-A: 301780089903
GTIN storage (14 digits): 00301780089903
FER_11945_L008990R0520_Ferralet retail label 90ct_FNL_VP.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b82b4008-22fd-05f5-6cc6-c0a6e81c65b8Product name220240805
910c1bd7-67d1-44c7-ad4f-9445f827edccProduct name120230808
91c62db0-0295-c81c-d10a-0856c259edd6Product name220200428
d32bc2b8-0bb7-2216-87aa-24639646e202Product name320190619
c5cd4727-ac49-4409-82b1-5bd8006c3ec7Product name120171122
d206bb34-ea65-399d-70d9-834f22dc2c18Product name320170724

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
0178-0089-902021-01-06C16284748780-19d75b9d0-490c-f424-e053-dadaa90a57ceFerralet ® 90 90 mg Dual-Iron Delivery
0178-0089-902020-01-31C16284748780-19d75b9d0-490c-f424-e053-dadaa90a57ceFerralet ® 90 90 mg Dual-Iron Delivery

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0178-0089-90Ferralet 9090 in 1 BOTTLETABLET, FILM COATED908

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0178-0089-90EA - Each0178-0089e3708453-ed7e-4df7-b053-15dc0479f0c512012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 17 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0178-00890178-0089-90

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 14 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Ferralet 90IRON, FOLIC ACID, CYANOCOBALAMIN, ASCORBIC ACID, AND DOCUSATE SODIUMMission Pharmacal Company0be2918e-55b3-4c66-aba0-09099a1c77702026-01-07Boxed warning, Warnings, Adverse reactionsExact identifier
ndc (package): 0178-0089-90
ndc (product): 0178-0089
ndc11 (package): 00178008990
spl id: 47d48d1f-2aa3-6c05-e063-6294a90a0b21
spl set id: 0be2918e-55b3-4c66-aba0-09099a1c7770

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.